Beyond the KRAS test

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 398-399

  Laurent Puig, Pierre ^a,b   Lièvre, Astrid ^a,b   Blons, Hélène ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIREGULIN; IRINOTECAN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; IMMUNOHISTOCHEMISTRY; KRAS GENE; METASTASIS; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; GENES, ERBB-1; GENETIC MARKERS; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS;

EID: 70349120293     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70063-2     Document Type: Article

References (18)

1. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96 (2007) 1166-1169
2. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25 (2007) 3230-3237
3. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19 (2008) 508-515
4. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
5. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
6. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 (2008) 374-379
7. Linardou H., Dahabreh I.J., Kanaloupiti D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008) 962-972
8. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
9. Cappuzzo F., Finocchiaro G., Rossi E., et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19 (2008) 717-723
10. Frattini M., Saletti P., Romagnani E., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97 (2007) 1139-1145
11. Sartore-Bianchi A., Moroni M., Veronese S., et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25 (2007) 3238-3245
12. Italiano A., Follana P., Caroli F.X., et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 15 (2008) 649-654
13. Lenz H.J., Van Cutsem E., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 (2006) 4914-4921
14. Vallbohmer D., Zhang W., Gordon M., et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 23 (2005) 3536-3544
15. Moroni M., Sartore-Bianchi A., Veronese S., and Siena S. EGFR FISH in colorectal cancer: what is the current reality?. Lancet Oncol 9 (2008) 402-403
16. Personeni N., Fieuws S., Piessevaux H., et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hydridization study. Clin Cancer Res 14 (2008) 5969-5976
17. Jhawer M., Goel S., Wilson A.J., et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68 (2008) 1953-1961
18. Perrone F., Lampis A., Orsenigo M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20 (2009) 84-90